当前位置: X-MOL 学术Cell Prolif. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
IL2RG ‐deficient minipigs generated via CRISPR/Cas9 technology support the growth of human melanoma‐derived tumours
Cell Proliferation ( IF 8.5 ) Pub Date : 2020-09-01 , DOI: 10.1111/cpr.12863
Jilong Ren 1, 2, 3 , Dawei Yu 1, 2 , Rui Fu 1, 2 , Peipei An 4 , Renren Sun 4 , Zhengzhu Wang 4 , Runfa Guo 1, 2 , Haoyun Li 1, 2 , Ying Zhang 1, 2 , Ziyi Li 4 , Yong-Guang Yang 4 , Wei Li 1, 2, 3 , Tang Hai 1, 2 , Zheng Hu 4
Affiliation  

Immunodeficient mice injected with human cancer cell lines have been used for human oncology studies and anti‐cancer drug trials for several decades. However, rodents are not ideal species for modelling human cancer because rodents are physiologically dissimilar to humans. Therefore, anti‐tumour drugs tested effective in rodents have a failure rate of 90% or higher in phase III clinical trials. Pigs are similar to humans in size, anatomy, physiology and drug metabolism rate, rendering them a desirable pre‐clinical animal model for assessing anti‐cancer drugs. However, xenogeneic immune rejection is a major barrier to the use of pigs as hosts for human tumours. Interleukin (IL)‐2 receptor γ (IL2RG), a common signalling subunit for multiple immune cytokines including IL‐2, IL‐4, IL‐7, IL‐9, IL‐15 and IL‐21, is required for proper lymphoid development.

中文翻译:

通过 CRISPR/Cas9 技术产生的 IL2RG 缺陷小型猪支持人类黑色素瘤衍生肿瘤的生长

几十年来,注射人类癌细胞系的免疫缺陷小鼠已被用于人类肿瘤学研究和抗癌药物试验。然而,啮齿动物并不是模拟人类癌症的理想物种,因为啮齿动物在生理上与人类不同。因此,在啮齿动物中测试有效的抗肿瘤药物在 III 期临床试验中的失败率高达 90% 或更高。猪在体型、解剖结构、生理学和药物代谢率方面与人类相似,使其成为评估抗癌药物的理想临床前动物模型。然而,异种免疫排斥是使用猪作为人类肿瘤宿主的主要障碍。白细胞介素 (IL)-2 受体 γ (IL2RG),多种免疫细胞因子的常见信号亚单位,包括 IL-2、IL-4、IL-7、IL-9、IL-15 和 IL-21,
更新日期:2020-09-01
down
wechat
bug